Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

Abstract Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD). Case presentation A 53-year-old woman with HIV/hep...

Full description

Bibliographic Details
Main Authors: José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó
Format: Article
Language:English
Published: BMC 2020-01-01
Series:BMC Nephrology
Subjects:
Ambrisentan
Hemodialysis
Pulmonary arterial hypertension
HIV-infection
Drug interactions
Online Access:https://doi.org/10.1186/s12882-019-1659-5

Internet

https://doi.org/10.1186/s12882-019-1659-5

Similar Items